Category: Life Sciences
Life Sciences market research reports by FirstWord
-
Tomorrow’s MSLs
Tomorrow’s MSLs Explore the evolving role of MSLs in the dynamic landscape of healthcare and pharmaceuticals Discover the future of Medical Science Liaisons (MSLs) in our latest report, Tomorrow's MSLs. This report delves into the evolving role of MSLs within the pharmaceutical industry, highlightin ... Read More
-
Payer Perspectives on Digital Health
Payer Perspectives on Digital Health How to win payer support for digital health solutions Accelerated by the COVID-19 pandemic, both patients and physicians have bought into the convenience offered by virtual health technologies. So, how have payers responded? While many have initiated virtual hea ... Read More
-
Biosimilars: US Payer Perspectives
Biosimilars: US Payer Perspectives Establishing biosimilar interchangeability, patent litigation, negative stakeholder attitudes, poor discounts, and defensive originator strategies have underpinned the sluggish development of the US biosimilar market. So, what would payers like to see? Will adalimu ... Read More
-
US Public Health Spending on Biosimilars: a data driven analysis
US Public Health Spending on Biosimilars: a data driven analysis Which companies and products are shaping the US biosimilar public health spending sector? Biosimilars are a useful way to contain pharmaceutical expenditure for both payers and patients. By the end of 2020, the FDA had approved 29 bios ... Read More
-
Meeting the Scientific Communication Needs of Multiple Stakeholders
Meeting the Scientific Communication Needs of Multiple Stakeholders How can medical affairs meet the diverse scientific information needs of multiple stakeholders? The timely delivery of trusted, current and relevant scientific data to key stakeholder groups is an increasingly critical medical affai ... Read More
-
RWE in Gene Therapy: Payer Views
RWE in Gene Therapy: Payer Views How to harness RWE to win payer support for gene therapies Gene therapy developers are looking beyond rare diseases to treat a broader range of conditions. While payers are positive for new therapies that treat unmet clinical need there is a growing anxiety: can the ... Read More
-
Biosimilars: US Payer Insights
Biosimilars: US Payer Insights Why might 2023 be a good year for the US biosimilars market? Delayed regulation, stakeholder anxieties, disappointing discounts and aggressive originator defence strategies have all played their part in the sluggish US biosimilar sector development. But is that about t ... Read More
-
Applying AI to Drug Discovery and Development: Issues and Challenges
Applying AI to Drug Discovery and Development: Issues and Challenges Pharma has invested heavily in Artificial Intelligence (AI) enabled technologies in the hope they would drive R&D efficiency gains. From identifying new targets and making screening more efficient to de-risking and accelerating cli ... Read More
-
Advances in Telemedicine
Advances in Telemedicine COVID-19 rapidly accelerated the use of telemedicine technologies and their acceptance by HCPs and patients is now well established. Favourable regulation and rising reimbursement is further seeing telehealth embedded in the healthcare ecosystem. So, where does pharma fit in ... Read More
-
Advances in Wearable Health Technology
Advances in Wearable Health Technology With the roll out of 5G, increasingly sophisticated biosensor technologies and the establishment of digital biomarkers, wearables are expanding into clinical settings. How–and where–can pharma benefit? In what ways can wearables be used to improve patient adher ... Read More
-
Commercial Workforce Excellence: Future training strategies and priorities
Commercial Workforce Excellence: Future training strategies and priorities In the future, commercial teams will only achieve their sales objectives through intelligence-led engagement that meet the needs of customers. Personalised omnichannel engagement will dominate physician/HCP interaction. Under ... Read More
-
Orphan Drugs: New thinking on RWE generation and value
Orphan Drugs: New thinking on RWE generation and value From clinical trial planning and better education of HCPs to meeting the demands of diverse stakeholder groups, real-world evidence (RWE) is increasingly playing a pivotal role in the successful development and launch of an orphan drug. But how ... Read More
-
Recruiting for the Medical Affairs Team of the Future
Recruiting for the Medical Affairs Team of the Future As Medical Affairs transitions to a core strategic function new capabilities will be needed to meet wider commitments such as controlling the scientific narrative, generating better evidence and delivering enhanced stakeholder engagement. New ski ... Read More
-
Cell and Gene Therapies: Accelerating uptake
Cell and Gene Therapies: Accelerating uptake Cell and gene therapies (CAGTs) are delivering on the promise of personalised medicines, meeting high unmet need and delivering powerful and curative treatments. So why is uptake so slow? The obstacles are diverse with the low volume of patients impacting ... Read More
-
Orphan Drugs: Pharma/DTC genetic testing partnerships
Orphan Drugs: Pharma/DTC genetic testing partnerships The rapidly developing field of direct-to-consumer (DTC) genetic testing offers orphan drug developers the opportunity to directly support patients and HCPs while unlocking new insights in rare diseases that can inform clinical development progra ... Read More
-
Medical Launch Readiness in a Virtual World
Medical Launch Readiness in a Virtual World From RWE generation to the delivery of personalised medical information, digital technology is enabling medical affairs to take a central role in product launch preparation. But is pharma getting full value from its medical affairs team? Why should medical ... Read More
-
The Rise of Patient Support Programs: Opportunities for Pharma
The Rise of Patient Support Programs: Opportunities for Pharma Advanced, well-designed patient support programs (PSP) are central to pharma’s patient centricity agenda and can deliver multiple stakeholder and commercial benefits. But challenges remain. How can you build awareness of your PSP? In wh ... Read More
-
Digital Twins: Trends and Opportunities
Digital Twins: Trends and Opportunities Second generation digital twins have the potential to transform pharma’s business, clinical research and manufacturing processes while driving the personalised medicine agenda and improving chronic disease diagnosis. But can developers overcome significant cha ... Read More
Research Assistance
